Shutai Shen (300204.SZ) BDB-001 Injection (indications for ANCA-associated vasculitis) Phase I/II Clinical Study Summary Report

Smart Finance News APP, Shu Tai Shen (300204.SZ) announced that the company has obtained the summary report of the I/II clinical study on BDB-001 injection (indication for ANCA-associated vasculitis, AAV). The product has shown good effectiveness in controlling disease remission in the completed I/II clinical trials, and has good safety and tolerability. The company will actively promote the III clinical trial to further verify its clinical benefits for patients with AAV.